Interviews

Chris Smith

2024-04-05

NeoGenomics, based in Southwest Florida, is a leading oncology diagnostic testing company in the United States with laboratories across the country.

Dr. Garo Armen

Chairman & CEO

Agnus

2024-04-03

Our focus at Agenus is on treating patients who are gravely ill. If someone is facing a prognosis of death within a year, and their remaining life is expected to be painful and difficult, they might prefer to try a new treatment.

Murali Aravamudan

Co-Founder & CEO

nference

2024-04-03

EMRs have the potential to encapsulate a patient’s complete medical history in a digital format, making it accessible and analyzable

Paul Billings

CEO & Director

Biological Dynamics, Inc

2024-04-03

Our primary focus at Biological Dynamics is on early-stage cancer diagnostics, particularly for pancreatic and other cancers, where early detection drastically improves life expectancy.

Michael Shpigelmacher

CEO & Founder

Bionaut Labs

2024-04-02

In five years, Bionaut Labs will hopefully be recognized as a pioneer and a major platform company in the field of remote-controlled micro-robots, potentially as a public entity or a substantial private organization.

Bryan Dechairo

President, CEO & Director

Sherlock Biosciences

2024-04-02

Our primary focus is on launching our first product, an over-the-counter test for chlamydia and gonorrhea, by 2025.

Brenda Bailey

Minister for Jobs

Economic Development and Innovation British Columbia

2024-04-02

British Columbia is reversing its talent drain by creating attractive local opportunities, highlighted by the return of professionals like a UBC PhD who worked in Germany for two decades.

Declan Hamill

VP of Policy

Legal & Regulatory Affairs, Innovative Medicines Canada

2024-04-02

This future involves overcoming systemic challenges through multisector partnerships and by maintaining the importance of life sciences in policy-making, streamlining sequential regulatory processes, and adopting more flexible approval and reimbursement mechanisms.

Gaurav Shah MD

Chief Executive Officer

Rocket Pharma

2024-04-02

Our therapy has enabled patients, who otherwise faced poor prognosis, to return to what we believe are normal activities, highlighting the potential of gene therapy to address not just Danon Disease but also other genetic cardiac conditions.

Dr. Lindsay Rosenwald

CEO

Fortress Biotech

2024-04-02

We're excited about several near-term products, including a novel treatment for adult rosacea by Journey Medical, which has a PDUFA goal date of November 4, 2024, and we believe could significantly impact the market with its impressive efficacy against the standard of care in clinical trials.

Pagina 80 din 172